<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468087</url>
  </required_header>
  <id_info>
    <org_study_id>ANTIVIRAL</org_study_id>
    <nct_id>NCT04468087</nct_id>
  </id_info>
  <brief_title>Antiviral Agents Against COVID-19 Infection</brief_title>
  <official_title>Antiviral Agents Against SARS-CoV-2 Infection: a Randomized, Double Blinded, Placebo Controlled, Multi-arm, Multi-stage Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent
      that would decrease the peak viral load and, consequently, the associated degree of
      immunopathological damage that follows this phase. The clinically approved substances
      considered for this study are used for treatment of other virus diseases, like influenza
      (favipiravir), HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of
      COVID-19 among patients under treatment for these aforementioned viruses is empirical less
      common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that
      patients with COVID-19 could benefit from treatments with favipiravir, atazanavir, sofosbuvir
      and daclatasvir.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded, multicenter, multi-arm, multi stage, study. COVID-19 confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) hospitalized patients with ≤ 7 days duration of symptoms will be randomly assigned to receive antivirals with potential effectiveness for SARS-CoV-2.
The study is planned to be an adaptive phase II / III study. The phase II will be divided into 2 stages: first and second stages. First stage will allocate patients into a 4:4:4:4:1:1:1:1 allocation ratio (4 for each treatment group and 1 for placebo) and second stage will allocate into 3:3:3:1:1:1 (3 for each antiviral combination and 1 for placebo). The phase 3 study will then proceed in a 2:1 allocation (2 chosen treatments for each Placebo).
A minimum of 125 and maximum of 900 participants will be included, considering that this is an adaptive study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in area under the curve of SARS-COV 2 viral load</measure>
    <time_frame>days 3, 6 and 9 after randomization</time_frame>
    <description>Change in area under the SARS-COV 2 viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial dose of 60mg, followed by 30mg every 8 hours for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofusbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg (1 capsule) twice daily on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Favipiravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1800 mg (9 capsules) twice daily on the first day and 800 mg (4 capsules) twice daily for the next 13 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Atazanavir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Daclatasvir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sofusbuvir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Favipiravir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 13 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.</description>
    <arm_group_label>Atazanavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>initial dose of 60mg, followed by 30mg every 8 hours for 10 days.</description>
    <arm_group_label>Daclatasvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofusbuvir</intervention_name>
    <description>400 mg (1 capsule) twice daily on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days.</description>
    <arm_group_label>Sofusbuvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>1800 mg (9 capsules) twice daily on the first day and 800 mg (4 capsules) twice daily for the next 13 days.</description>
    <arm_group_label>Favipiravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Atazanavir</intervention_name>
    <description>2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
    <arm_group_label>Placebo Atazanavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Daclatasvir</intervention_name>
    <description>2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
    <arm_group_label>Placebo Daclatasvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sofusbuvir</intervention_name>
    <description>1 capsule twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.</description>
    <arm_group_label>Placebo Sofusbuvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Favipiravir</intervention_name>
    <description>9 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 13 days.</description>
    <arm_group_label>Placebo Favipiravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (≥ 18 years) hospitalized with COVID-19:

               -  SARS-CoV-2 positive RT-PCR or

               -  Typical clinical history and chest CT with typical findings, pending RT-PCR for
                  SARS-CoV-2

          2. Symptom duration&gt; = 7 days

          3. At least 1 of the following prognostic factors:

               -  SpO2 &lt;= 94% in room air or need for supplemental oxygen to maintain SpO2&gt; 94%

               -  Lymphocyte count &lt;800 / microL

          4. The patient consents to participate in the study and is willing to comply with all
             study procedures, including the collection of virology samples

        Exclusion Criteria:

          1. Patients in need of respiratory support with CNAF, NIV or invasive mechanical
             ventilation;

          2. Alanine Transaminase (ALT) or Aspartate Transaminase (AST)&gt; 5 times the upper limit of
             normal;

          3. Renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;30 mL / min / 1.73 m2,
             using the MDRD or CKD-EPI method);

          4. History of liver disease (liver cirrhosis);

          5. Decompensated congestive heart failure;

          6. Pregnant or lactating patients;

          7. Known allergy or hypersensitivity to any study drug;

          8. Hepatitis C carrier (HCV RNA positive), active Hepatitis B (positive surface antigen
             in the past), or HIV (ELISA and confirmatory Western Blot in the past). New screening
             tests are NOT required;

          9. Patients currently using nucleoside or nucleotide analog drugs for any indication;

         10. Corrected Q interval T&gt; 480 on the electrocardiogram;

         11. Heart rate &lt;55 bpm;

         12. Chronic use of amiodarone;

         13. Women of childbearing potential and men with a child of childbearing potential who do
             NOT agree to use two contraceptive methods (including barrier method) for 100 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Israel Maia, PhD</last_name>
    <phone>11 +55113053 6611</phone>
    <phone_ext>8206</phone_ext>
    <email>israels.maia@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital do Coracao</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04005-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

